JP2018035162A5 - - Google Patents

Download PDF

Info

Publication number
JP2018035162A5
JP2018035162A5 JP2017172825A JP2017172825A JP2018035162A5 JP 2018035162 A5 JP2018035162 A5 JP 2018035162A5 JP 2017172825 A JP2017172825 A JP 2017172825A JP 2017172825 A JP2017172825 A JP 2017172825A JP 2018035162 A5 JP2018035162 A5 JP 2018035162A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
superoxide dismutase
agent according
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017172825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018035162A (ja
JP6382416B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018035162A publication Critical patent/JP2018035162A/ja
Publication of JP2018035162A5 publication Critical patent/JP2018035162A5/ja
Application granted granted Critical
Publication of JP6382416B2 publication Critical patent/JP6382416B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017172825A 2011-09-26 2017-09-08 疾患の治療方法 Active JP6382416B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539365P 2011-09-26 2011-09-26
US61/539,365 2011-09-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014532075A Division JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145207A Division JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2018035162A JP2018035162A (ja) 2018-03-08
JP2018035162A5 true JP2018035162A5 (enExample) 2018-08-02
JP6382416B2 JP6382416B2 (ja) 2018-08-29

Family

ID=47911939

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014532075A Active JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法
JP2017172825A Active JP6382416B2 (ja) 2011-09-26 2017-09-08 疾患の治療方法
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014532075A Active JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Country Status (8)

Country Link
US (5) US9149483B2 (enExample)
EP (1) EP2760874A4 (enExample)
JP (6) JP6267638B2 (enExample)
CN (2) CN103906756B (enExample)
AU (5) AU2012316397B2 (enExample)
CA (2) CA3120505C (enExample)
HK (1) HK1199261A1 (enExample)
WO (1) WO2013048965A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045559A2 (en) 2006-10-12 2008-04-17 Activbiotics Methods of treating oral mucositis
HK1199261A1 (en) * 2011-09-26 2015-06-26 Galera Labs, Llc Methods for treatment of diseases
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
EP3738967A1 (en) 2015-08-11 2020-11-18 Galera Labs, LLC Pentaaza macrocyclic ring complexes possessing oral bioavailability
EA201892510A3 (ru) 2016-05-03 2019-09-30 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная терапия для лечения рака
WO2018045348A2 (en) 2016-09-01 2018-03-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
EP3582753A4 (en) * 2017-02-15 2020-12-16 Galera Labs, LLC MACROCYCLIC PENTAAZA RING COMPLEXES FOR LOCAL INTESTINAL ADMINISTRATION
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
AU2019215032A1 (en) * 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CN114502179A (zh) * 2019-10-10 2022-05-13 加莱拉实验室有限责任公司 含锰配合物的水性制剂的制备方法、制剂和治疗方法
US20230071463A1 (en) * 2020-02-13 2023-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
WO2025259817A1 (en) * 2024-06-12 2025-12-18 Galera Labs, Llc Methods for reduced tissue damage from radiopharmaceuticals with superoxide-reducing agent

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
ES2113952T3 (es) 1991-07-19 1998-05-16 Monsanto Co Complejos de manganeso con ligandos macrociclicos nitrogenados eficaces como catalizadores para dismutar superoxidos.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2188530A1 (en) 1994-04-22 1995-11-02 John Charles Alexander Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
PL324993A1 (en) * 1995-08-17 1998-07-06 Monsanto Co Bioconjugates of macrocyclic, nitrogen containing manganese complex ligands efficiently acting as catalysts of the superoxidic dismutation reaction
JPH11511168A (ja) 1995-08-17 1999-09-28 モンサント カンパニー 窒素含有大環状リガンドの金属錯体の生体分子結合体を使用する診断造影検査方法
NZ315505A (en) 1995-08-17 2000-01-28 Monsanto Co Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
DE60018925T2 (de) * 1999-05-27 2006-04-13 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
EP1194150A4 (en) 1999-06-23 2003-06-11 Eric F Bernstein USE OF NITROXIDES TO Heal Wounds And To Prevent Radiation Damage To Skin
JP5074652B2 (ja) 2000-02-08 2012-11-14 ライスユニバーシティ 治療法および診断法において使用される光学活性なナノ粒子
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP2004507487A (ja) 2000-08-29 2004-03-11 メファ・アクチェンゲゼルシャフト 腸疾患治療薬
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1347773B1 (en) * 2001-01-05 2010-04-14 Metaphore Pharmaceuticals Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
AU2002248366B2 (en) * 2001-01-19 2006-10-26 Aeolus Sciences, Inc. Cancer therapy
AU2002236861A1 (en) 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
EP2988125B1 (en) 2001-03-02 2019-05-08 Galera Labs, LLC Manganese(ii) pentaazacycloalkane complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
HU230378B1 (hu) 2001-11-01 2016-03-29 Uab Research Foundation Anti-DR5 ellenanyagok és anti-DR4 ellenanyagok és más terápiás ágensek kombinációi
JP2005513063A (ja) * 2001-12-14 2005-05-12 アルコン，インコーポレイティド 眼の障害および疾患の治療用スーパーオキシドジスムターゼ模擬体
JP2005530738A (ja) 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び／又は治療のためのクルクミン
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
BRPI0509359A (pt) 2004-03-29 2007-09-04 Inotek Pharmaceuticals Corp compostos de porfirina substituìda por piridila e métodos de empregos destes
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20090099150A1 (en) 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
AR053566A1 (es) 2005-03-31 2007-05-09 Schering Corp Compuestos espiriciclicos antagonistas de los receptores de trombina
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
US20100158857A1 (en) 2006-05-23 2010-06-24 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008045559A2 (en) 2006-10-12 2008-04-17 Activbiotics Methods of treating oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
WO2009033726A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
EP2259776A4 (en) 2008-02-29 2011-03-16 Eagle Pharmaceuticals Inc USEFUL TOPOTECAN SOLUTIONS
MX2010011307A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2009143454A2 (en) * 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
HK1199261A1 (en) * 2011-09-26 2015-06-26 Galera Labs, Llc Methods for treatment of diseases
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
EP3738967A1 (en) 2015-08-11 2020-11-18 Galera Labs, LLC Pentaaza macrocyclic ring complexes possessing oral bioavailability
EA201892510A3 (ru) 2016-05-03 2019-09-30 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная терапия для лечения рака
WO2018045348A2 (en) 2016-09-01 2018-03-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
WO2018125862A1 (en) 2016-12-27 2018-07-05 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
EP3582753A4 (en) 2017-02-15 2020-12-16 Galera Labs, LLC MACROCYCLIC PENTAAZA RING COMPLEXES FOR LOCAL INTESTINAL ADMINISTRATION
WO2018191676A1 (en) 2017-04-13 2018-10-18 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Similar Documents

Publication Publication Date Title
JP2018035162A5 (enExample)
JP2018184465A5 (enExample)
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
JP2020183416A5 (enExample)
JP2014526562A5 (enExample)
CN105452258B (zh) 使用双核金(i)化合物用于癌症治疗的方法
JP2015524444A5 (enExample)
JP2013067645A5 (enExample)
JP2011503111A5 (ja) ４−ヨード−３−ニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる乳がんの治療
JP2015523397A5 (enExample)
KR20160006668A (ko) 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물
JP2018533589A5 (enExample)
JP2016527202A5 (enExample)
JP2020523356A5 (enExample)
JP2013518124A5 (enExample)
CN109970987A (zh) Mof材料、纳米载药材料、药物组合物及其应用
JP2019530706A5 (enExample)
JP2014508758A5 (enExample)
TW201141472A (en) Method to treat small cell lung cancer
JP2014517078A5 (enExample)
Wong Total marrow irradiation: redefining the role of radiotherapy in bone marrow transplantation
RU2015139515A (ru) Комбинированное лечение
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
JP2018516964A (ja) 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
CN115837042B (zh) 当归补血汤在制备增强免疫检查点抑制剂疗效的药物中的应用